We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

41 hedge funds and large institutions have $133M invested in Xilio Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.2% less ownership

Funds ownership: 5.09% → 4.88% (-0.2%)

2% less funds holding

Funds holding: 42 → 41 (-1)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

56% less capital invested

Capital invested by funds: $303M → $133M (-$170M)

Holders
41
Holders Change
-1
Holders Change %
-2.38%
% of All Funds
0.65%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
3
Increased
8
Reduced
13
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
State Street
State Street
Massachusetts
+$392K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$231K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$85K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$76.7K
5
TRCT
Tower Research Capital (TRC)
New York
+$37.7K

Top Sellers

1
DM
Deerfield Management
New York
-$852K
2
CCM
CAAS Capital Management
New York
-$592K
3
MIM
Monashee Investment Management
Massachusetts
-$578K
4
GCM
Ghisallo Capital Management
Massachusetts
-$480K
5
DKCM
Davidson Kempner Capital Management
New York
-$458K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$19.8M – – –
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$19.5M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$18.3M +$231K +1,461 +0.8%
DM
4
Deerfield Management
New York
$14.7M -$852K -5,384 -3%
RCM
5
RA Capital Management
Massachusetts
$14.2M – – –
RVM
6
RiverVest Venture Management
Missouri
$10.2M – – –
RSCM
7
Rock Springs Capital Management
Maryland
$8.42M – – –
AIIC
8
AJU IB Investment Company
South Korea
$4.72M – – –
SCM
9
Soleus Capital Management
Connecticut
$3.38M – – –
AG
10
Artal Group
Luxembourg
$3.18M – – –
Vanguard Group
11
Vanguard Group
Pennsylvania
$2.94M -$88.6K -560 -2%
HMC
12
Harvard Management Company
Massachusetts
$2.94M – – –
Norges Bank
13
Norges Bank
Norway
$2.83M – – –
BlackRock
14
BlackRock
New York
$2.12M -$275K -1,739 -8%
Fidelity International
15
Fidelity International
Bermuda
$1.55M – – –
MIM
16
Monashee Investment Management
Massachusetts
$1.15M -$578K -3,656 -24%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1M +$85K +537 +6%
State Street
18
State Street
Massachusetts
$664K +$392K +2,475 +59%
Northern Trust
19
Northern Trust
Illinois
$449K +$6.17K +39 +0.9%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$149K +$76.7K +485 +48%
Charles Schwab
21
Charles Schwab
California
$114K – – –
N
22
Nuveen
North Carolina
$80K – – –
GPCM
23
Granite Point Capital Management
Massachusetts
$71K – – –
New York State Common Retirement Fund
24
New York State Common Retirement Fund
New York
$40K +$633 +4 +1%
JP Morgan Chase
25
JP Morgan Chase
New York
$34K -$77.4K -489 -59%
1
2

XLO Hedge Fund Activity: Q1 2022 in Review

41 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2022, worth a combined $133M — down 56% from $303M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of XLO and 3 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 8 added.

The largest buyer was State Street, adding an estimated $392K. The largest seller was Deerfield Management, cutting an estimated $852K.

  • 41 institutional investors held Xilio Therapeutics (XLO) as of Q1 2022, down from 42 in Q4 2021.
  • Funds reported $133M of Xilio Therapeutics stock for Q1 2022, down 56% quarter-over-quarter.
  • 3 funds opened new Xilio Therapeutics positions in Q1 2022 and 4 closed out, a net change of -1 holder.
  • The largest Xilio Therapeutics buyer in Q1 2022 was State Street, an estimated $392K added.
  • The largest Xilio Therapeutics seller in Q1 2022 was Deerfield Management, an estimated $852K sold.

Based on aggregated 13F filings for Q1 2022.